Spotlight: R&D portfolios rarely become inefficient because of one bad investment decision. More often, the economics deteriorate quietly as complexity accumulates.
One more development program. Another indication. Another device variant. Another geography. Another platform or legacy program competing for scarce capabilities.
Each investment may make sense individually. But collectively, they create costs that traditional project-level economics often fail to capture: fragmented expertise, resource contention, governance burden, slower decisions, longer development cycles and diluted leadership attention.
In my post, “The Cost of Complexity: How R&D Portfolios Quietly Erode Pharma and MedTech Margins,” I explore why portfolio complexity should be treated as an economic variable—not simply an organizational inconvenience.
The question for R&D leadership is no longer only “Are we investing in the right projects?”
It is also “What is the enterprise cost of carrying all of them simultaneously?”
For Pharma and MedTech companies looking to improve R&D productivity and margins, portfolio simplification can sometimes create more value than trying to make every individual project incrementally more efficient.
Read full post below…
#Pharma #MedTech #RDStrategy #PortfolioStrategy #RDProductivity #LifeSciences
One more development program. Another indication. Another device variant. Another geography. Another platform or legacy program competing for scarce capabilities.
Each investment may make sense individually. But collectively, they create costs that traditional project-level economics often fail to capture: fragmented expertise, resource contention, governance burden, slower decisions, longer development cycles and diluted leadership attention.
In my post, “The Cost of Complexity: How R&D Portfolios Quietly Erode Pharma and MedTech Margins,” I explore why portfolio complexity should be treated as an economic variable—not simply an organizational inconvenience.
The question for R&D leadership is no longer only “Are we investing in the right projects?”
It is also “What is the enterprise cost of carrying all of them simultaneously?”
For Pharma and MedTech companies looking to improve R&D productivity and margins, portfolio simplification can sometimes create more value than trying to make every individual project incrementally more efficient.
Read full post below…
#Pharma #MedTech #RDStrategy #PortfolioStrategy #RDProductivity #LifeSciences
When R&D leaders discuss profitability, attention naturally goes to the visible numbers such as development spend, clinical costs, headcount, timelines, probability of success etc.
But one cost rarely appears as a separate line item and that is— The cost of portfolio complexity.
Complexity accumulates gradually: One more development program. Another indication. An additional device variant. A market-specific requirement. A technology platform that needs continued support. A legacy program that remains strategically relevant enough to retain resources.
Individually, each decision can be justified. Collectively, they can create an R&D portfolio that is significantly more expensive to operate than the sum of its projects.
Why? Because every additional layer of complexity creates coordination, governance and resource costs across the organization.
Specialized capabilities become fragmented across programs. Clinical, regulatory, quality and engineering teams manage competing priorities. Governance expands. Dependencies multiply. Leadership attention gets diluted. And scarce expertise is spread across a growing number of initiatives.
Eventually, the economic impact shows up in ways that are easy to attribute elsewhere: Longer development cycles. Higher overhead. Slower decisions. Resource bottlenecks. Lower productivity. Delayed time to value.
This is particularly relevant in Pharma and MedTech, where complexity can compound across products, platforms, indications, geographies, regulatory pathways, organizational work culture and lifecycle investments.
The strategic question, therefore, is not simply “Which projects should be in our R&D portfolio?” It is also— “What is the economic cost of carrying this level of portfolio complexity?”
That distinction matters.
A portfolio can contain individually attractive programs and still be economically inefficient at the enterprise level. This is why I believe complexity-adjusted portfolio economics deserves more attention in R&D strategy.
Portfolio reviews should look beyond individual project NPV, technical feasibility or strategic fit. Leadership teams also need visibility into the cumulative burden the portfolio places on critical capabilities, decision processes and organizational capacity.
It is important to take note that sometimes the next improvement in R&D profitability will not come from making every project 10% more efficient. Rather, it may come from simplifying the system in which those projects compete for resources.
For Pharma and MedTech leadership teams examining R&D productivity, portfolio complexity is worth treating as an economic variable—not simply an organizational inconvenience.
The question I would put on the executive agenda is— Are we measuring the return from each R&D investment without adequately measuring the cost of carrying them all together?
I work at the intersection of R&D strategy, portfolio economics and operating performance. If your R&D portfolio is growing faster than the organization’s capacity to execute it, I help Pharma and MedTech leadership teams identify where portfolio complexity is consuming ‘value’—and translate that insight into sharper investment, prioritization and profitable operating decisions. If this is on your agenda, let’s connect.
But one cost rarely appears as a separate line item and that is— The cost of portfolio complexity.
Complexity accumulates gradually: One more development program. Another indication. An additional device variant. A market-specific requirement. A technology platform that needs continued support. A legacy program that remains strategically relevant enough to retain resources.
Individually, each decision can be justified. Collectively, they can create an R&D portfolio that is significantly more expensive to operate than the sum of its projects.
Why? Because every additional layer of complexity creates coordination, governance and resource costs across the organization.
Specialized capabilities become fragmented across programs. Clinical, regulatory, quality and engineering teams manage competing priorities. Governance expands. Dependencies multiply. Leadership attention gets diluted. And scarce expertise is spread across a growing number of initiatives.
Eventually, the economic impact shows up in ways that are easy to attribute elsewhere: Longer development cycles. Higher overhead. Slower decisions. Resource bottlenecks. Lower productivity. Delayed time to value.
This is particularly relevant in Pharma and MedTech, where complexity can compound across products, platforms, indications, geographies, regulatory pathways, organizational work culture and lifecycle investments.
The strategic question, therefore, is not simply “Which projects should be in our R&D portfolio?” It is also— “What is the economic cost of carrying this level of portfolio complexity?”
That distinction matters.
A portfolio can contain individually attractive programs and still be economically inefficient at the enterprise level. This is why I believe complexity-adjusted portfolio economics deserves more attention in R&D strategy.
Portfolio reviews should look beyond individual project NPV, technical feasibility or strategic fit. Leadership teams also need visibility into the cumulative burden the portfolio places on critical capabilities, decision processes and organizational capacity.
It is important to take note that sometimes the next improvement in R&D profitability will not come from making every project 10% more efficient. Rather, it may come from simplifying the system in which those projects compete for resources.
For Pharma and MedTech leadership teams examining R&D productivity, portfolio complexity is worth treating as an economic variable—not simply an organizational inconvenience.
The question I would put on the executive agenda is— Are we measuring the return from each R&D investment without adequately measuring the cost of carrying them all together?
I work at the intersection of R&D strategy, portfolio economics and operating performance. If your R&D portfolio is growing faster than the organization’s capacity to execute it, I help Pharma and MedTech leadership teams identify where portfolio complexity is consuming ‘value’—and translate that insight into sharper investment, prioritization and profitable operating decisions. If this is on your agenda, let’s connect.
Disclaimer: This article reflects observed industry trends and professional perspectives and does not constitute regulatory, legal, or operational advice. Read full disclaimer here.
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #PortfolioStrategy #RDProductivity #Profitability #Innovation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #PortfolioStrategy #RDProductivity #Profitability #Innovation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
Subscribe to Operational Excellence Academy YouTube channel: |  |
